FDA Grants Breakthrough Therapy Designation for Roche/Genentech's Investigational Medicine ACE910 for People With Hemophilia A With Factor VIII Inhibitors
September 04, 2015 at 04:43 AM EDT
Genentech, a member of the Roche Group (OTC: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has granted ...
